首页> 外文期刊>Animal Pharm Weekly Briefing >Simparica and Cytopoint surpass $100m, with another blockbuster in Zoetis' pipeline
【24h】

Simparica and Cytopoint surpass $100m, with another blockbuster in Zoetis' pipeline

机译:Simparica Cytopoint超过100美元,另一个重磅Zoetis的管道

获取原文
获取原文并翻译 | 示例
           

摘要

"Isoxazolines are the only class indicated to treat sarcoptic mange - a highly contagious dermatologic parasite in dogs. Prior to oral isoxazolines like Simparica, veterinarians were primarily dispensing topical ectoparasite products, which are less appealing to many dog owners. Now they have more flexible options for safe, monthly flea and tick protection."Dr Kausche said the success of collars, such as Bayer's Seresto, "proved there is room for long-acting external antiparasitics in the companion animal space".Klaus Hellman, who is managing director and founder of contract research organization Klifovet,said: "The success of Seresto is rather surprising, as collars had been thought to be old fashioned and dead."
机译:“Isoxazolines唯一的类表示治疗sarcoptic兽疥癣——一个高度传染性在狗狗皮肤寄生虫。isoxazolines Simparica,兽医主要是分配局部皮肤产品,吸引许多狗的主人。安全,每月只跳蚤和蜱虫的保护。Kausche说成功的衣领,如拜耳的Seresto”,证明了存在的空间长效外部抗的伴侣动物空间”。创始人兼董事总经理的合同研究机构Klifovet说:“成功的Seresto相当令人惊讶的项圈被认为是过时且死了。”

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号